白细胞介素-2治疗肿瘤的临床疗效观察

目的：评价白细胞介素-2(IL-2)对肝癌、胃癌、大肠癌及食道癌等消化系统恶性肿瘤的临床效果，不良反应。方法：根据IL-2的Ⅰ期临床研究结果，每次给予IL-2药10万单位，肌注，每日2次，连续用药3—6个月。第3个月结束时评价疗效，完全缓解、部分缓解及无变化继续用药至6个月，病情进展立即停药。结果：112例可评价疗效的患中，完全缓解29例，部分缓解37例，总有效率58．9％，肝癌、胃、大肠癌及食道癌的有效率分别为66．7％、53．8％、60．o％、53．6％。不良反应包括恶心、呕吐、腹痛等，大多为Ⅰ-Ⅱ度，可耐受。结论：IL-2对肝癌、胃癌、大肠癌及食道癌等消化系统恶性肿瘤疗效肯定，副作用轻，是一个有价值及治疗前景的抗癌药物。     

白细胞介素-2、黄芪与化疗药联合治疗中晚期肿瘤疗效观察

笔用白细胞介素-2(1L-2)、黄芪与化疗药联合应用治疗中晚期癌肿11倒，其疗效比单用化疗好。     

紫杉醇治疗口腔鳞癌临床疗效的初步研究

目的：研究紫杉醇对口腔鳞癌的治疗效果，探讨合理用药方案。方法：11例口腔鳞癌患者经静脉给予紫杉醇并联合其它化学药物进行临床治疗，按标准记录患者的疗效、体重变化及毒副反应。结果：有效率为37＝5％，无明显不良反应，无瘤生存5例。结论：紫杉醇对晚期口腔鳞癌治疗疗效显著，联合应用铂类制剂有协同作用。     

CO2激光联合干扰素α-2b局部注射治疗尖锐湿疣的疗效观察

目的 观察干扰素α-2b局部注射治疗尖锐湿疣的临床疗效。方法 治疗组采用CO2激光联合干扰素α-2b局部注射治疗。对照组采用CO2激光治疗，对两组患者的治愈率进行比较。结果 治疗组35例治愈26例，治愈率74．29％，对照组33例，治愈16例，治愈率48．48％，两组治愈率比较，差异有显著性（X^2=4．79，P〈0．05）。结论 CO2激光联合干扰素α-2b局部注射治疗尖锐湿疣，可明显提高疗效，降低复发，可供临床应用。     

重组干扰素α-2b局部注射治疗尖锐湿疣临床观察

目的：评价重组α－2b干扰素局部注射治疗尖锐湿疣的疗效及安全性。:方法：首诊病人在高频电刀切除疣体后，第一个月每周在疣体基底部注射α－2b干扰素100万^u，如为泛发，每个疣体注射不少于0．2ml；第二个月每二周1次；第三个月1次，随访1个月未见复发，表示治愈。如有复发，重复治疗3个月。并与单用阿昔洛韦口服作对比，结果：治疗组72例痊愈33例，显效28例，有效率为85．9％，对照组50例，病愈6例，显效17例，有效率为46％，两者比较有非常显著的意义。结论：重组干扰素α－2b局部注射治疗尖锐湿疣抗病毒，增强机体免疫力效果好，在首诊时电刀切除疣体后，重组干扰素α－2b按疗程治疗，抗复发效果明显优于其它治疗方案。     

顺铂与白细胞介素-2联合治疗恶性腹水23例临床观察

现报道顺铂与白细胞介素2联合腹腔内注入治疗恶性腹水23例，取得较满意疗效。     

白细胞介素-2辅助治疗老年慢性阻塞性肺病的疗效观察

目的应用白细胞介素-2(IL-2)辅助治疗老年慢性阻塞性肺病急性发作并观察其疗效。方法79例老年慢性阻塞性肺病急性发作患者随机分为治疗组与对照组,对照组应用常规抗感染、对症、支持治疗,治疗组在上述基础上加用IL-2治疗,并观察患者症状、体征、X线胸片、血白细胞变化情况。结果治疗组对发热、发绀、呼吸困难的改善及其肺部口罗音的消失优于对照组(P<0.05),治疗1周X线胸片肺部病灶吸收情况与对照组比较差异有显著性(P<0.05);但对咳嗽、水肿两组间差异无显著性(P>0.05), IL-2对血白细胞恢复正常未显出优越性(P> 0.05),加用IL-2治疗老年慢性阻塞性肺病有效率高于对照组,两组间差异有显著性(P<0.05)。结论IL-2对老年慢性阻塞性肺病急性发作有良好的辅助治疗效果。     

白细胞介素-2联合化疗治疗白血病对血清IFN -7、IL - 10、IL -2水平的影响和疗效分析

目的 研究白细胞介素-2(IL-2)联合化疗治疗白血病对血清干扰素一7(IFN-7)、白细胞介素-10(IL-10)、IL-2水平的影响和疗效.方法 选取2017年3月一2020年3月郑州中心医院收治的白血病患者80例,采用随机数字表法将其分为对照组和研究组,各40例.对照组采用化疗,研究组采用IL-2联合化疗.两组连...     

中西医结合治疗慢性心力衰竭近期疗效观察

目的观察中西医结合治疗慢性心力衰竭的近期疗效。方法收集笔者所在医院2010年1月-2013年1月收治的慢性心力衰竭患者86例,随机分西医组和中西医组,每组43例,分别给予常规西药治疗以及中西医结合治疗,并观察治疗效果。结果在中医证候积分、基础心率、6min步行试验、LVEF方面,中西医组治疗后较西医组治疗后明显改善（P〈0．05）。中西医组治疗总有效率明显高于西医组（P〈0．05）。结论中西医结合治疗慢性心力衰竭具有明显的优势,值得在临床上推广应用。     

Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib

Sorafenib is a multikinase inhibitor that displays antiproliferative and antiangiogenic properties in the treatment of solid tumors. Commonly administered for the treatment of metastatic or unresectable hepatocellular carcinoma and advanced renal cell carcinoma, sorafenib has demonstrated remarkable survival benefits for those where curative surgery is not an option. Although generally having a mild side effect profile, sorafenib has been linked to a variety of dermatologic disorders, including most commonly acneiform rash, hand-foot-skin reactions, facial erythema, splinter subungual hemorrhages, alopecia or pruritus. The authors describe a case of sorafenib-induced eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient with hepatocellular carcinoma. This case adds to the growing literature suggesting a strong correlation between sorafenib and non-melanoma skin cancers including keratoacanthoma and squamous cell carcinoma. Routine dermatologic monitoring of these patients to ensure early detection is highly recommended. J Drugs Dermatol. 2011;10(3):308-310.     

Phase II study of a novel oral formation of 5-fluorouracil in combination with low-dose cisplatin as preoperative chemotherapy of oral squamous cell carcinoma

TS-1 is a novel oral 5-fluorouracil containing tegaful (prodrug of 5-FU) and two biochemical modulators. These modulators feature effect-enhancing and adverse reaction-reducing activity. We investigated the histological response and toxicities of combination chemotherapy with TS- 1 and low-dose cisplatin and evaluated its usefulness as preoperative chemotherapy Forty-four newly diagnosed patients with stage Il-IV oral squamous cell carcinoma were enrolled in this study from February 2002 to April 2004. Patients were administered TS-1 80 mg/m2/day (days 1-14) and cisplatin 5 mg/m2/day (days 1-5 and 8-12) followed by radical surgery within 2 weeks. The histopathological effect of chemotherapy, which was a surrogate endpoint of this trial, was evaluated with surgical or biopsy specimens. The rate of histological antitumor effect was as follows: complete response (CR) 36.4%, partial response (PR) 25.0%, minor response (MR) 18.1% and no change (NC) 20.5%. The rate of histological response (CR + PR) was 61.4%. The CR rate of effective cases was 59.3%. The main toxicities occurred in bone marrow and the digestive tract. The incidence of severe toxicity such as grade 3 or 4 was 4.5% in anemia, 9% in leukocytopenia, 11.4% in neutropenia, 4.5% in thrombocytopenia and 2.3% in anorexia, diarrhea and urticaria. Most patients showed no toxicity or mild toxicities. TS- 1 with low-dose cisplatin has highly effective antitumor activity and mild toxicities. In particular, the CR rate was very high. It is suggested that this regimen is suitable for neoadjuvant chemotherapy. We expect that this chemotherapy will contribute to avoidance of surgery for small tumors (stages I and II) and will enable function-preserving surgery for advanced tumors.     

西妥昔单抗联合化疗用于晚期头颈部鳞癌的成本-效果分析

目的研究西妥昔单抗联合化疗用于晚期头颈部鳞癌患者的成本效果性。方法根据EXTREM E临床试验数据,结合我国医疗费用及消费水平,进行成本-效果分析,并对结果进行敏感度分析。结果西妥昔单抗联合化疗方案相较于单纯化疗方案,每例患者总生存期增加1个月,需多花费50 327.0元人民币。结论西妥昔单抗联合化疗方案相对于单纯化疗方案不具有成本效果优势。     

紫龙金片联合化疗治疗大肠癌的临床观察

摘要：目的：观察紫龙金片联合由奥沙利铂(Oxaliplatin)、亚叶酸钙(CF)、氟尿嘧啶(5-Fu)组成的FOLFOX4方案及单用FOLFOX4方案化疗治疗大肠癌的疗效及不良反应。方法：45例接受化疗的大肠癌患者分为单用化疗组(对照组)及化疗并用紫龙金片组(治疗组)。结果：治疗组与对照组疗效评价比较,无统计学意义(p>0．05);KPS评分治疗组与对照组比较,差异有统计学意义(p<0．05);在骨髓抑制及恶心、呕吐副反应方面治疗组与对照组比较有统计学意义（P<0．05）。结论：紫龙金片联用FOLFOX4方案与单用FOLFOX4方案化疗治疗大肠癌相比能减轻化疗毒副作用,提高生活质量。      

Investigations on cell-mediated immunity in patients with breast and ovarian carcinomas receiving a combination of chemotherapy and immunotherapy with thymopentin

In 78 patients with breast and 37 patients with ovarian cancer the effect of combined chemo- and immunotherapy with thymopentin (Timunox, Cilag) on different parameters of cell-mediated immunity (leukocyte migration inhibition test, serum level of TNF-alpha, IL-1, interferon-alpha, distribution of lymphocyte subsets) and the clinical course of disease was evaluated and compared to patients receiving only chemotherapy. In cancer patients additionally treated with thymopentin an increase in reactivity in the LMI test and an increase of IFN-alpha serum levels could be observed, whereas serum levels of TNF-alpha and IL-2 and the distribution of T-helper, T-suppressor, total T and natural killer cells did not change. Concerning the clinical course of disease, no significant differences could be observed in patients with disseminated spread of disease, whereas in patients receiving combined chemo-immunotherapy in the course of an adjuvant treatment a benefit was found compared to those receiving only chemotherapy. Thus, it seems that the additional administration of thymopentin in breast and ovarian cancer patients under chemotherapy results in a reduction of immunosuppressive side effects of chemotherapy and a positive effect of the survival time in patients with limited spread of disease.     

亮菌口服液辅助治疗新生儿高胆红素血症疗效观察

目的研究亮菌口服液辅助治疗新生儿高胆红素血症的疗效。方法选择笔者所在医院2010年9月～2011年9月住院的60例新生儿高胆红素血症患儿,随机分为治疗组和对照组。治疗组给予亮菌口服液,配合常规治疗如微生态制剂、光疗等;对照组仅给予常规治疗。结果治疗组血清总胆红素、直接胆红素较对照组降低,差异有统计学意义(P<0.05)。结论亮菌口服液辅助治疗新生儿高胆红素血症疗效显著。     

埃克替尼联合放疗对鼻咽高分化鳞癌细胞系的增敏效应

目的探讨埃克替尼对鼻咽高分化鳞癌细胞系CNE-1的放射增敏作用。方法细胞培养鼻咽癌CNE-1,分为空白对照组、埃克替尼组(0.094、0.188、0.376μmol·L-1)、照射组(照射剂量分别为0、2、4、8 Gy)和实验组(各浓度埃克替尼+各剂量照射组),利用多靶单击数学模型拟合放射剂量-细胞存活曲线,MTT法观察药物对体外培养的CNE-1细胞凋亡的影响,荧光染色法检测凋亡细胞,流式细胞术分析药物对CNE-1细胞周期的影响,高倍光镜下观察细胞形态。结果埃克替尼作用后,0.094、0.188、0.376μmol·L-1的放射增敏比分别为1.095、1.433、1.639,随药物浓度增加而变大;通过流式细胞仪检测发现,埃克替尼和放射治疗具有协同作用,可使CNE-1细胞周期发生改变,凋亡指数增加,0.376μmol·L-1埃克替尼+照射8Gy的凋亡指数达(50.82±6.54)%。结论埃克替尼对鼻咽高分化鳞癌细胞系CNE-1有明显的放射增敏效应。     

口腔鳞癌术后VP辅助化疗过程中血象变化的初步分析

目的分析观察口腔鳞癌术后VP（长春新碱＋平阳霉素）辅助化疗血象变化情况及分析引起变化的可能原因。方法对2000年1月～2005年12月我科收治81例口腔鳞癌术后患者行VP方案辅助化疗前、化疗结束后一日及一周血常规资料进行回顾性对比分析。结果VP方案化疗结束一日后,大多数患者血细胞发生不同程度的升高,其中白细胞变化最显著（P〈0.05）,血小板次之（P〈0.05）,红细胞不明显（P〉0.05）;而化疗结束后一周,血细胞均恢复至化疗前水平（P〉0.05）。结论口腔鳞癌VP方案化疗后,患者血细胞可能会发生暂时性的升高,化疗结束后一周基本恢复正常。